Basilea Pharmaceutica (CH:BSLN)
:BSLN
Want to see CH:BSLN full AI Analyst Report?
BSLN Stock Chart & Stats
CHF52.60
CHF0.45(0.96%)
At close: 4:00 PM EST
CHF52.60
CHF0.45(0.96%)
Day’s Range― - ―
52-Week RangeCHF44.70 - CHF59.70
Previous CloseN/A
Volume30.09K
Average Volume (3M)41.01K
Market Cap
CHF612.52M
Enterprise ValueCHF716.01M
Total Cash (Recent Filing)CHF162.34M
Total Debt (Recent Filing)CHF100.93M
Price to Earnings (P/E)18.8
Beta0.99
Next Earnings
Aug 18, 2026EPS Estimate
3.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.65
Shares Outstanding13,425,260
10 Day Avg. Volume32,790
30 Day Avg. Volume41,007
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)5.22
Price to Sales (P/S)2.88
P/FCF Ratio11.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF70.00Price Target Upside33.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)3.92
Revenue Forecast (FY)CHF254.92M
Bulls Say, Bears Say
Bulls Say
AI-driven Discovery PartnershipPartnership with Phare Bio to apply artificial intelligence could accelerate discovery and development of novel antibiotics, strengthening Basilea's early-stage pipeline.
Fosmanogepix Successor PotentialFosmanogepix as a potential successor to Cresemba could secure regulatory approvals in multiple territories ahead of Cresemba sales decline, offering a pathway to sustain long-term antifungal revenue.
Global Cresemba Commercial ReachCresemba's approval and marketing in more than 70 countries and solid commercial momentum support sales-based milestone payments that enhance revenue visibility for the antifungal franchise.
Bears Say
Clinical Development Risk For FosmanogepixSetbacks in clinical development of fosmanogepix would jeopardize the planned successor strategy and could materially slow Basilea's growth trajectory.
Partner Execution Risk For Marketed DrugsDependence on partners to optimize isavuconazole and ceftobiprole globally creates execution risk that could limit revenue capture if partners fail to commercialize effectively.
Portfolio Concentration And Milestone UncertaintyConcentration of value in a small number of antifungal assets and reliance on sales-triggered milestones could increase financial volatility if one product underperforms or misses targets.
Basilea Pharmaceutica News
BSLN FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was CHF44.70 and its highest was CHF59.70 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is CHF612.52M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Aug 18, 2026 which is in 64 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Feb 17, 2026. The company reported CHF1.988 earnings per share for the quarter, beating the consensus estimate of CHF1.637 by CHF0.351.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 3.34.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,425,260 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of CHF1.988 in its last earnings report, beating expectations of CHF1.637. Following the earnings report the stock price went down -1.257%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in CH:BSLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
BSLN Stock 12 Month Forecast
Average Price Target
CHF70.00
▲(33.08% Upside)
Technical Analysis
Molecular Partners AG
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---